Stevanato Group S.p.A. (STVN) Benefits from the Uptick in Biologics - KeyBanc
Tweet Send to a Friend
KeyBanc analyst Paul Knight reiterated an Overweight rating and $32.00 price target on Stevanato Group S.p.A. (NYSE: STVN) on the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
